Symbols / PGEN
PGEN Chart
About
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis; and AG019, which is in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.41B |
| Enterprise Value | 1.39B | Income | -425.87M | Sales | 6.31M |
| Book/sh | 0.12 | Cash/sh | 0.34 | Dividend Yield | — |
| Payout | 0.00% | Employees | 143 | IPO | — |
| P/E | — | Forward P/E | -18.09 | PEG | — |
| P/S | 223.21 | P/B | 33.73 | P/C | — |
| EV/EBITDA | -13.20 | EV/Sales | 219.57 | Quick Ratio | 3.81 |
| Current Ratio | 4.04 | Debt/Eq | 234.53 | LT Debt/Eq | — |
| EPS (ttm) | -1.42 | EPS next Y | -0.22 | EPS Growth | — |
| Revenue Growth | 206.60% | Earnings | 2026-03-19 | ROA | -52.83% |
| ROE | -5.08% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -11.80% | Profit Margin | 0.00% | Shs Outstand | 353.82M |
| Shs Float | 165.29M | Short Float | 18.35% | Short Ratio | 11.14 |
| Short Interest | — | 52W High | 5.47 | 52W Low | 1.11 |
| Beta | 1.07 | Avg Volume | 4.30M | Volume | 5.73M |
| Target Price | $8.50 | Recom | None | Prev Close | $4.08 |
| Price | $3.98 | Change | -2.45% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.50
Mean price target
2. Current target
$3.98
Latest analyst target
3. DCF / Fair value
$-2.43
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.98
Low
$8.00
High
$9.00
Mean
$8.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-14 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-08-19 | main | JMP Securities | Market Outperform → Market Outperform | $8 |
| 2025-08-19 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-08-15 | up | JP Morgan | Underweight → Neutral | — |
| 2025-08-15 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-06-12 | reit | JMP Securities | Market Outperform → Market Outperform | $6 |
| 2025-05-15 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-03-20 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $6 |
| 2025-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-01-23 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-01-22 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-01-14 | reit | JMP Securities | Market Outperform → Market Outperform | $5 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-08-15 | main | JMP Securities | Market Outperform → Market Outperform | $7 |
| 2024-08-15 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-06-04 | reit | JMP Securities | Market Outperform → Market Outperform | $14 |
| 2024-06-03 | main | Stifel | Buy → Buy | $10 |
| 2024-06-03 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-05-15 | reit | Cantor Fitzgerald | — → Overweight | — |
- $PGEN stock is down 8% today. Here's what we see in our data. - Quiver Quantitative Wed, 18 Feb 2026 19
- Precigen Reports Third Quarter 2025 Financial Results and Business Updates - PR Newswire hu, 13 Nov 2025 08
- Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech (NASDAQ:PGEN) - Seeking Alpha Wed, 11 Feb 2026 08
- New RRP treatment spreads nationwide as more insurers agree to cover it - Stock Titan Mon, 12 Jan 2026 08
- Precigen, Inc. (NASDAQ:PGEN) is definitely on the radar of institutional investors who own 31% of the company - Yahoo Finance Sun, 14 Dec 2025 08
- Trade Alert: Independent Director Of Precigen Jeffrey Kindler Has Sold Stock - simplywall.st hu, 18 Dec 2025 08
- Commit To Buy Precigen At $4, Earn 26.2% Using Options - Nasdaq ue, 17 Feb 2026 16
- PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug - Yahoo Finance Mon, 25 Aug 2025 07
- Insider Purchase: Chief Operating Officer of $PGEN Buys 2,000 Shares - Quiver Quantitative ue, 30 Sep 2025 07
- Precigen (NASDAQ: PGEN) schedules Nov. 13 4:30 PM ET conference call to review results - Stock Titan hu, 06 Nov 2025 08
- Precigen Is Still A Buy After The Papzimeos Rally (NASDAQ:PGEN) - Seeking Alpha ue, 25 Nov 2025 08
- HC Wainwright & Co. Maintains Precigen (PGEN) Buy Recommendation - Nasdaq Fri, 14 Nov 2025 08
- Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ... - Yahoo Finance hu, 13 Nov 2025 08
- $125M Non-Dilutive Deal: Precigen Secures Major Funding for Revolutionary HPV Immunotherapy Launch - Stock Titan Wed, 03 Sep 2025 07
- $PGEN stock is up 8% today. Here's what we see in our data. - Quiver Quantitative ue, 16 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1900036 | 7942150.0 | — | Sale at price 4.18 per share. | KIRK RANDAL JOE | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-22 00:00:00 | I |
| 1 | 235467 | 855899.0 | — | Sale at price 3.63 per share. | KINDLER JEFFREY B | Director | — | 2025-12-12 00:00:00 | D |
| 2 | 2966293 | 12291748.0 | — | Sale at price 3.83 - 4.47 per share. | KIRK RANDAL JOE | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-21 00:00:00 | I |
| 3 | 174360 | 604192.0 | — | Sale at price 3.38 - 3.60 per share. | KINDLER JEFFREY B | Director | — | 2025-09-30 00:00:00 | D |
| 4 | 1809667 | 6170964.0 | — | Sale at price 3.41 per share. | KIRK RANDAL JOE | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-30 00:00:00 | I |
| 5 | 6000 | 21480.0 | — | Purchase at price 3.58 per share. | TENNANT PHIL | Officer | — | 2025-09-29 00:00:00 | D |
| 6 | 11216 | 40016.0 | — | Purchase at price 3.42 - 3.62 per share. | THOMASIAN HARRY JR. | Chief Financial Officer | — | 2025-09-26 00:00:00 | D |
| 7 | 2000 | 6800.0 | — | Purchase at price 3.40 per share. | SHAH RUTUL R. | Chief Operating Officer | — | 2025-09-26 00:00:00 | D |
| 8 | 5000252 | 18653532.0 | — | Sale at price 3.68 - 3.86 per share. | KIRK RANDAL JOE | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-19 00:00:00 | I |
| 9 | 17385257 | nan | — | — | KIRK RANDAL JOE | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-17 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -564.73K | -51.50K | -2.65K | -782.94 |
| TaxRateForCalcs | 0.01 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -83.17M | -78.39M | -61.31M | -77.91M |
| TotalUnusualItems | -40.32M | -10.84M | -1.12M | -543.00K |
| TotalUnusualItemsExcludingGoodwill | -40.32M | -10.84M | -1.12M | -543.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -126.23M | -95.90M | -79.78M | -110.81M |
| ReconciledDepreciation | 4.53M | 6.67M | 10.77M | 13.76M |
| ReconciledCostOfRevenue | 4.27M | 6.12M | 6.34M | 5.75M |
| EBITDA | -123.50M | -89.23M | -62.43M | -78.45M |
| EBIT | -128.02M | -95.89M | -73.19M | -92.21M |
| NetInterestIncome | 1.41M | 2.77M | -6.64M | -18.58M |
| InterestExpense | 6.00K | 468.00K | 6.77M | 18.75M |
| InterestIncome | 1.42M | 3.24M | 133.00K | 171.00K |
| NormalizedIncome | -86.48M | -85.12M | -78.66M | -110.26M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -126.23M | -95.90M | 28.32M | -92.17M |
| TotalExpenses | 98.63M | 95.15M | 101.52M | 105.67M |
| TotalOperatingIncomeAsReported | -135.03M | -99.76M | -75.73M | -91.95M |
| DilutedAverageShares | 267.73M | 244.54M | 200.36M | 197.76M |
| BasicAverageShares | 267.73M | 244.54M | 200.36M | 197.76M |
| DilutedEPS | -0.47 | -0.39 | 0.14 | -0.47 |
| BasicEPS | -0.47 | -0.39 | 0.14 | -0.47 |
| DilutedNIAvailtoComStockholders | -126.23M | -95.90M | 28.32M | -92.17M |
| NetIncomeCommonStockholders | -126.23M | -95.90M | 28.32M | -92.17M |
| NetIncome | -126.23M | -95.90M | 28.32M | -92.17M |
| MinorityInterests | 0.00 | |||
| NetIncomeIncludingNoncontrollingInterests | -126.23M | -95.90M | 28.32M | -92.17M |
| NetIncomeDiscontinuousOperations | 0.00 | 0.00 | 108.09M | 18.64M |
| NetIncomeContinuousOperations | -126.23M | -95.90M | -79.78M | -110.81M |
| TaxProvision | -1.79M | -458.00K | -189.00K | -160.00K |
| PretaxIncome | -128.03M | -96.36M | -79.97M | -110.97M |
| OtherIncomeExpense | -34.73M | -10.21M | 1.28M | -978.00K |
| OtherNonOperatingIncomeExpenses | 5.59M | 627.00K | 1.54M | -432.00K |
| SpecialIncomeCharges | -40.32M | -10.84M | -1.12M | -543.00K |
| WriteOff | 543.00K | |||
| ImpairmentOfCapitalAssets | 40.32M | 10.84M | 1.12M | 543.00K |
| RestructuringAndMergernAcquisition | 0.00 | |||
| EarningsFromEquityInterest | 0.00 | 0.00 | 862.00K | -3.00K |
| NetNonOperatingInterestIncomeExpense | 1.41M | 2.77M | -6.64M | -18.58M |
| InterestExpenseNonOperating | 6.00K | 468.00K | 6.77M | 18.75M |
| InterestIncomeNonOperating | 1.42M | 3.24M | 133.00K | 171.00K |
| OperatingIncome | -94.70M | -88.92M | -74.61M | -91.41M |
| OperatingExpense | 94.36M | 89.03M | 95.18M | 99.93M |
| ResearchAndDevelopment | 53.07M | 48.61M | 47.17M | 47.93M |
| SellingGeneralAndAdministration | 41.29M | 40.41M | 48.01M | 51.99M |
| GrossProfit | -342.00K | 106.00K | 20.57M | 8.52M |
| CostOfRevenue | 4.27M | 6.12M | 6.34M | 5.75M |
| TotalRevenue | 3.92M | 6.22M | 26.91M | 14.27M |
| OperatingRevenue | 3.89M | 6.22M | 26.66M | 13.77M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 7.48M | |||
| OrdinarySharesNumber | 292.87M | 248.92M | 208.15M | 206.74M |
| ShareIssued | 292.87M | 256.40M | 208.15M | 206.74M |
| NetDebt | 38.36M | 143.51M | ||
| TotalDebt | 5.50M | 7.10M | 51.42M | 190.07M |
| TangibleBookValue | 14.92M | 51.19M | 44.88M | 17.50M |
| InvestedCapital | 38.51M | 118.50M | 169.48M | 287.28M |
| WorkingCapital | 80.90M | 45.77M | 39.51M | 121.98M |
| NetTangibleAssets | 14.92M | 51.19M | 44.88M | 17.50M |
| CapitalLeaseObligations | 5.50M | 7.10M | 8.20M | 10.14M |
| CommonStockEquity | 38.51M | 118.50M | 126.26M | 107.35M |
| TotalCapitalization | 38.51M | 118.50M | 126.26M | 287.23M |
| TotalEquityGrossMinorityInterest | 38.51M | 118.50M | 126.26M | 107.35M |
| StockholdersEquity | 38.51M | 118.50M | 126.26M | 107.35M |
| GainsLossesNotAffectingRetainedEarnings | 12.00K | -1.95M | -3.49M | 203.00K |
| OtherEquityAdjustments | 12.00K | -1.95M | -3.49M | 203.00K |
| RetainedEarnings | -2.09B | -1.96B | -1.87B | -1.92B |
| AdditionalPaidInCapital | 2.13B | 2.08B | 2.00B | 2.02B |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 106.75M | 32.55M | 89.72M | 252.51M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 85.23M | 9.56M | 11.07M | 217.86M |
| OtherNonCurrentLiabilities | 50.00K | |||
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 3.67M | ||
| PreferredSecuritiesOutsideStockEquity | 28.22M | 0.00 | ||
| DerivativeProductLiabilities | 50.54M | 0.00 | ||
| NonCurrentDeferredLiabilities | 1.93M | 3.67M | 4.08M | 25.56M |
| NonCurrentDeferredRevenue | 1.93M | 1.82M | 1.82M | 23.02M |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 1.85M | 2.26M | 2.54M |
| LongTermDebtAndCapitalLeaseObligation | 4.55M | 5.89M | 6.99M | 188.63M |
| LongTermCapitalLeaseObligation | 4.55M | 5.89M | 6.99M | 8.75M |
| LongTermDebt | 179.88M | |||
| CurrentLiabilities | 21.52M | 22.98M | 78.64M | 34.65M |
| OtherCurrentLiabilities | 12.85M | |||
| CurrentDeferredLiabilities | 589.00K | 509.00K | 25.00K | 1.49M |
| CurrentDeferredRevenue | 589.00K | 509.00K | 25.00K | 1.49M |
| CurrentDebtAndCapitalLeaseObligation | 956.00K | 1.20M | 44.43M | 1.45M |
| CurrentCapitalLeaseObligation | 956.00K | 1.20M | 1.21M | 1.39M |
| CurrentDebt | 43.22M | 52.00K | ||
| OtherCurrentBorrowings | 43.22M | 52.00K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 8.42M | 8.25M | 6.38M | 7.86M |
| PayablesAndAccruedExpenses | 11.56M | 13.02M | 27.82M | 11.00M |
| CurrentAccruedExpenses | 8.03M | 11.30M | 23.75M | 7.82M |
| Payables | 3.53M | 1.73M | 4.07M | 3.19M |
| DuetoRelatedPartiesCurrent | 0.00 | 74.00K | ||
| AccountsPayable | 3.53M | 1.73M | 4.07M | 3.11M |
| TotalAssets | 145.27M | 151.04M | 215.98M | 359.86M |
| TotalNonCurrentAssets | 42.85M | 82.29M | 97.82M | 203.23M |
| OtherNonCurrentAssets | 459.00K | 846.00K | 1.15M | 46.27M |
| InvestmentsAndAdvances | 0.00 | 48.56M | ||
| InvestmentinFinancialAssets | 0.00 | 48.56M | ||
| AvailableForSaleSecurities | 48.56M | |||
| GoodwillAndOtherIntangibleAssets | 23.59M | 67.31M | 81.38M | 89.84M |
| OtherIntangibleAssets | 4.46M | 40.70M | 44.45M | 52.29M |
| Goodwill | 19.14M | 26.61M | 36.92M | 37.55M |
| NetPPE | 18.80M | 14.13M | 15.29M | 18.55M |
| AccumulatedDepreciation | -22.87M | -24.28M | -23.44M | -21.46M |
| GrossPPE | 41.67M | 38.41M | 38.73M | 40.01M |
| Leases | 4.48M | 4.38M | 4.33M | 3.37M |
| ConstructionInProgress | 9.02M | 1.58M | 531.00K | 1.83M |
| OtherProperties | 21.83M | 25.67M | 26.09M | 26.80M |
| MachineryFurnitureEquipment | 3.55M | 3.99M | 5.02M | 5.26M |
| BuildingsAndImprovements | 2.63M | 2.63M | 2.59M | 2.59M |
| LandAndImprovements | 164.00K | 164.00K | 164.00K | 164.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 102.41M | 68.75M | 118.16M | 156.63M |
| OtherCurrentAssets | 3.34M | 4.33M | 5.07M | 5.47M |
| AssetsHeldForSaleCurrent | 0.00 | 40.19M | ||
| RestrictedCash | 0.00 | 43.34M | 0.00 | |
| PrepaidAssets | 6.74M | |||
| Inventory | 287.00K | 326.00K | ||
| OtherInventories | 272.00K | 303.00K | ||
| FinishedGoods | 8.11M | |||
| WorkInProcess | 2.56M | |||
| RawMaterials | 15.00K | 23.00K | ||
| Receivables | 1.16M | 1.57M | 13.80M | 1.98M |
| OtherReceivables | 237.00K | 673.00K | 12.83M | 566.00K |
| DuefromRelatedPartiesCurrent | 19.00K | 73.00K | ||
| NotesReceivable | 0.00 | |||
| AccountsReceivable | 926.00K | 902.00K | 978.00K | 1.34M |
| AllowanceForDoubtfulAccountsReceivable | 0.00 | -184.00K | -184.00K | -184.00K |
| GrossAccountsReceivable | 926.00K | 1.09M | 1.16M | 1.52M |
| CashCashEquivalentsAndShortTermInvestments | 97.91M | 62.85M | 55.95M | 108.66M |
| OtherShortTermInvestments | 68.39M | 55.28M | 51.09M | 72.24M |
| CashAndCashEquivalents | 29.52M | 7.58M | 4.86M | 36.42M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -76.76M | -68.47M | -69.97M | -63.02M |
| RepaymentOfDebt | 0.00 | -43.22M | -155.29M | -466.00K |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 110.24M | 72.81M | 0.00 | 121.05M |
| CapitalExpenditure | -8.58M | -1.54M | -4.92M | -7.25M |
| InterestPaidSupplementalData | 7.00K | 1.17M | 8.54M | 7.16M |
| IncomeTaxPaidSupplementalData | 4.00K | 21.00K | 0.00 | 36.00K |
| EndCashPosition | 29.52M | 7.85M | 48.60M | 43.34M |
| BeginningCashPosition | 7.85M | 48.60M | 43.34M | 52.25M |
| EffectOfExchangeRateChanges | -27.00K | -320.00K | -827.00K | 217.00K |
| ChangesInCash | 21.70M | -40.43M | 6.08M | -9.12M |
| FinancingCashFlow | 110.58M | 29.59M | -155.29M | 121.19M |
| CashFlowFromContinuingFinancingActivities | 110.58M | 29.59M | -155.29M | 121.19M |
| NetOtherFinancingCharges | -588.00K | |||
| ProceedsFromStockOptionExercised | 346.00K | 0.00 | 1.00K | 608.00K |
| NetPreferredStockIssuance | 79.00M | 0.00 | 0.00 | |
| PreferredStockIssuance | 79.00M | 0.00 | 0.00 | |
| NetCommonStockIssuance | 31.24M | 72.81M | 0.00 | 121.05M |
| CommonStockIssuance | 31.24M | 72.81M | 0.00 | 121.05M |
| NetIssuancePaymentsOfDebt | 0.00 | -43.22M | -155.29M | -466.00K |
| NetShortTermDebtIssuance | 0.00 | 0.00 | ||
| ShortTermDebtPayments | 0.00 | 0.00 | ||
| ShortTermDebtIssuance | 0.00 | 0.00 | ||
| NetLongTermDebtIssuance | 0.00 | -43.22M | -155.29M | -466.00K |
| LongTermDebtPayments | 0.00 | -43.22M | -155.29M | -466.00K |
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -20.71M | -3.09M | 226.42M | -74.54M |
| CashFromDiscontinuedInvestingActivities | 0.00 | 0.00 | 162.31M | 0.00 |
| CashFlowFromContinuingInvestingActivities | -20.71M | -3.09M | 64.11M | -74.54M |
| NetOtherInvestingChanges | 60.00K | 98.00K | 594.00K | 6.76M |
| NetInvestmentPurchaseAndSale | -12.19M | -1.65M | 68.44M | -74.05M |
| SaleOfInvestment | 175.02M | 183.38M | 68.44M | 100.17M |
| PurchaseOfInvestment | -187.21M | -185.03M | 0.00 | -174.22M |
| NetBusinessPurchaseAndSale | 0.00 | |||
| SaleOfBusiness | 0.00 | |||
| PurchaseOfBusiness | 0.00 | |||
| NetPPEPurchaseAndSale | -8.58M | -1.54M | -4.92M | -7.25M |
| PurchaseOfPPE | -8.58M | -1.54M | -4.92M | -7.25M |
| OperatingCashFlow | -68.17M | -66.93M | -65.05M | -55.77M |
| CashFlowFromContinuingOperatingActivities | -68.17M | -66.93M | -65.05M | -55.77M |
| ChangeInWorkingCapital | 4.52M | 17.07M | -35.70M | -804.00K |
| ChangeInOtherWorkingCapital | 3.34M | 5.71M | -23.43M | 4.51M |
| ChangeInOtherCurrentLiabilities | -55.00K | -107.00K | -144.00K | 47.00K |
| ChangeInOtherCurrentAssets | 120.00K | 129.00K | -101.00K | 305.00K |
| ChangeInPayablesAndAccruedExpense | -278.00K | -1.64M | -1.14M | 2.28M |
| ChangeInAccruedExpense | -1.83M | 782.00K | -1.52M | 1.86M |
| ChangeInPayable | 1.55M | -2.42M | 379.00K | 420.00K |
| ChangeInAccountPayable | 1.55M | -2.42M | 379.00K | 420.00K |
| ChangeInPrepaidAssets | 981.00K | 748.00K | 2.63M | -1.38M |
| ChangeInInventory | 2.34M | -1.90M | ||
| ChangeInReceivables | 414.00K | 12.23M | -13.51M | -6.56M |
| ChangesInAccountReceivables | -24.00K | 76.00K | -2.17M | -6.23M |
| OtherNonCashItems | -1.02M | -13.07M | -79.98M | 6.50M |
| StockBasedCompensation | 9.47M | 9.89M | 10.21M | 13.90M |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | 0.00 | ||
| ProvisionandWriteOffofAssets | 0.00 | 0.00 | 944.00K | 1.27M |
| AssetImpairmentCharge | 40.32M | 10.84M | 1.12M | 543.00K |
| AmortizationOfSecurities | -883.00K | -1.81M | 832.00K | 1.23M |
| DeferredTax | -1.79M | -479.00K | -150.00K | -167.00K |
| DeferredIncomeTax | -1.79M | -479.00K | -150.00K | -167.00K |
| DepreciationAmortizationDepletion | 4.53M | 6.67M | 10.77M | 13.76M |
| DepreciationAndAmortization | 4.53M | 6.67M | 10.77M | 13.76M |
| AmortizationCashFlow | 3.06M | 4.85M | ||
| AmortizationOfIntangibles | 3.06M | 4.85M | ||
| Depreciation | 1.47M | 1.82M | ||
| OperatingGainsLosses | 2.91M | -132.00K | -1.40M | 153.00K |
| EarningsLossesFromEquityInvestments | 0.00 | 0.00 | -862.00K | 3.00K |
| NetForeignCurrencyExchangeGainLoss | 2.92M | 0.00 | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -126.23M | -95.90M | 28.32M | -92.17M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PGEN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|